Financial Performance - The company's operating revenue for Q3 2024 was ¥89,552,626.84, representing a 137.26% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2024 was -¥6,489,699.32, with a year-to-date net profit of -¥46,889,888.23[5]. - Total operating revenue for the first three quarters of 2024 reached ¥231,030,545.43, a significant increase from ¥150,665,541.41 in the same period of 2023, representing a growth of approximately 53.3%[33]. - The net loss for the first three quarters of 2024 was ¥46,889,888.23, an improvement from a net loss of ¥96,582,500.85 in the same period of 2023, reflecting a reduction of approximately 51.5%[36]. - The total comprehensive loss for the first three quarters of 2024 was ¥46,889,888.23, compared to a loss of ¥96,582,500.85 in 2023, reflecting a reduction of approximately 51.5%[39]. Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥64,056,674.63[7]. - In the first three quarters of 2024, the cash inflow from operating activities was CNY 273,547,756.34, compared to CNY 260,896,973.39 in the same period of 2023, representing an increase of approximately 4.3%[40]. - The net cash outflow from operating activities in the first three quarters of 2024 was CNY -64,056,674.63, worsening from CNY -21,150,724.69 in the first three quarters of 2023[44]. - The total cash outflow from operating activities was CNY 337,604,430.97 in the first three quarters of 2024, compared to CNY 282,047,698.08 in the same period of 2023, reflecting an increase of approximately 19.7%[44]. - The ending cash and cash equivalents balance as of the end of the third quarter of 2024 was CNY 121,210,711.78, down from CNY 448,275,862.91 at the end of the same period in 2023, a decrease of approximately 73.0%[46]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,205,651,919.73, a decrease of 25.79% from the end of the previous year[8]. - The total liabilities decreased to ¥710,481,179.23 from ¥743,026,871.85, a decline of about 4%[28]. - The total current assets decreased to ¥495,170,740.50 from ¥881,533,254.03, a reduction of about 44%[28]. - The company's total liabilities decreased to ¥349,929,587.69 in 2024 from ¥693,517,978.39 in 2023, a reduction of approximately 49.6%[33]. - Long-term equity investments decreased to ¥28,760,795.15 from ¥40,874,881.63, a decline of about 30%[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,589[18]. - The largest shareholder, Lingkang Holdings Group Co., Ltd., holds 339,652,800 shares, accounting for 47.09% of total shares[18]. - The company repurchased 17,701,793 shares, representing 2.45% of total shares[24]. - There are no known related party relationships among the top shareholders, except for siblings among some of them[22]. Operational Highlights - The company reported a significant increase in its core product lines, with a 117.21% growth in existing formulations and a 100% growth in pharmaceutical distribution compared to the same period last year[13]. - The company has been focusing on cost control and maximizing production capacity to improve profitability[13]. - The company plans to continue expanding its market presence and product offerings in the upcoming quarters[13]. Earnings and Expenses - The basic earnings per share for Q3 2024 was -¥0.01, with a year-to-date figure of -¥0.07[8]. - Research and development expenses decreased to ¥14,987,666.90 in 2024 from ¥21,226,696.58 in 2023, showing a decline of about 29.5%[33]. - The basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.07, an improvement from -¥0.13 in the same period of 2023[39]. - The company recorded a financial expense of -¥19,037,217.99 in 2024, a notable improvement from a financial expense of ¥430,723.86 in 2023[33]. - The company reported a financial asset impairment loss of ¥46,298.03 in 2024, compared to a loss of ¥1,989,226.07 in 2023, indicating a significant improvement[36].

证券代码：603669 证券简称：灵康药业 公告编号：2024-078 灵康药业集团股份有限公司 关于上海证券交易所对公司 2024 年第三季度报告 监管工作函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）于近日收 到上海证券交易所上市公司管理二部下发的《关于灵康药业 2024 年第三季度报 告信息披露的监管工作函》（上证公函【2024】3605 号）（以下简称"《监管工 作函》"）。根据相关规定，现对《监管工作函》提及的相关问题回复如下： 一、三季报显示，2024 年前三季度公司实现营业收入 2.31 亿元，同比上 升 53.34%，同时扣除非经常性损益后的净利润继续亏损 0.91 亿元。公司实现 营业收入增长的主要原因为，报告期内扩展存量制剂业务以及拓展新业务。其 中，新增商业配送业务较上年同期增长 100%，存量制剂业务较上年同期增长 48.42%。请公司：（1）详细说明新增商业配送业务的具体情况，包括但不限于 商业模式、获客方式、开展期限情况 ...

灵康药业集团股份有限公司 关于控股股东部分股份办理质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至公告披露日,公司控股股东灵康控股集团有限公司（以下简称"灵 康控股"）直接持有公司股份 33,965.28 万股无限售流通股股票，占公司总股本 的 47.09%，灵康控股累计质押公司股票数量为 12,232.96 万股，占其持有公司 股份总数的 36.02%，占公司总股本的 16.96%。 截至目前，灵康控股所持股份的质押风险可控，不存在引发平仓或被强 制平仓的风险。 证券代码：603669 证券简称：灵康药业 公告编号：2024-076 2024 年 11 月 29 日，灵康药业集团股份有限公司（以下简称"灵康药业" 或"本公司"）接到公司控股股东灵康控股关于部分股份办理质押的通知，现将 相关情况公告如下： 一、本次股份质押情况 1、本次股份质押基本情况 | 股东 | 是否为 | 质押股数 | 是否为 | 是否 | 质押起始 | | 质押到期 | | | 占其所 | 占公司 | 质押融 | ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2024-074 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转换公司债券付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 灵康药业集团股份有限公司（以下简称"公司"）于 2020 年 12 月 1 日公开发 行的 A 股可转换公司债券（以下简称"灵康转债"），将于 2024 年 12 月 2 日开始 支付自 2023 年 12 月 1 日至 2024 年 11 月 30 日期间的利息。根据《灵康药业集 团股份有限公司公开发行 A 股可转换公司债券募集说明书》（以下简称"《募集 说明书》"）有关条款规定，现将有关事项公告如下： 一、本期债券的基本情况 8、债券期限：本次发行的可转债存续期限为自发行之日起 6 年，即 2020 年 12 月 1 日至 2026 年 11 月 30 日。 9、债券利率：本次发行的可转债票面利率设定为：第一年 0.40 ...

证券代码：603669 证券简称：灵康药业 公告编号：2024-073 灵康药业集团股份有限公司 关于收到上海证券交易所 2024 年第三季度报告信息披露的监管工作函的公告 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）于近日收 到上海证券交易所上市公司管理二部下发的《关于灵康药业 2024 年第三季度报 告信息披露的监管工作函》（上证公函【2024】3605 号）（以下简称"《监管工作 函》"）。根据相关规定，现将《监管工作函》全文公告如下： 灵康药业集团股份有限公司： 公司于 2024 年 10 月 31 日披露第三季度报告，经事后审核，根据本所《股 票上市规则》第 13.1.1 条的规定，请你公司进一步补充披露下述信息。 五大客户供应商有关情况，包括但不限于合作时间、是否与控股股东及关联方存 在关联关系，近三年来变动情况等。 二、三季报显示，报告期内公司销售商品、提供劳务收到的现金为 1.77 亿 元，同比减少 20.90%。此外，报告期末 ...

Group 1 - Lingkang Pharmaceutical (603669) experienced a decline of 8.01% in its stock price today, with a turnover rate of 8.01% and a trading volume of 387 million yuan [1] - The stock exhibited a volatility of 16.07% throughout the day, leading to its listing on the Shanghai Stock Exchange's watchlist [1] - Data from the Longhu list indicates that institutional investors collectively sold a net amount of 67.5 million yuan [1]

证券代码：603669 证券简称：灵康药业 公告编号：2024-072 剂型：注射剂 注册分类：化学药品 规格：1.25g（按 C₁₆H₁₆N₄O₈S 计） 受理号：CYHB2450250 上市许可持有人：海南灵康制药有限公司 灵康药业集团股份有限公司 关于子公司注射用头孢呋辛钠 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南灵康制药有限公司（以下简称"灵康制药"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于"注射用头孢呋辛钠"（以下简称 "该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性 评价。现将有关情况公告如下： 一、药品基本情况 （一）药物名称：注射用头孢呋辛钠 （二）药物名称：注射用头孢呋辛钠 剂型：注射剂 注册分类：化学药品 规格：1.75g（按 C₁₆H₁₆N₄O₈S 计） 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 生产企业：海南灵 ...

Financial Performance - Revenue for the first three quarters of 2024 reached 2.31 billion yuan, a year-on-year increase of 53.34% [1] - Net profit attributable to the parent company was -46.89 million yuan, with a reduction in loss of 51.45% [1] - Third-quarter revenue was 89.55 million yuan, a year-on-year increase of 137.26% [1] - Main pharmaceutical business grew by 48.42% year-on-year in the first three quarters [2] Strategic Initiatives - Participating in the 10th national centralized procurement for two products: Injection of Latamoxef Sodium and Injection of Esmolol Hydrochloride [2] - Entering the CMO business for the first time to maximize production capacity utilization [2] - Leveraging provincial alliance centralized procurement for core product Injection of Cefuroxime Sodium, covering 11 and 21 provinces respectively [2] - Implementing cost control measures through refined management [2] Product Portfolio - Injection of Latamoxef Sodium has a market capacity of approximately 3 billion yuan annually, with 9 qualified enterprises [2] - Injection of Huperzine A is a proprietary product with significant market potential, currently covering less than one-fifth of China [3][4] - Injection of Esmolol Hydrochloride has a market capacity of about 1.1 billion yuan, with 18 qualified enterprises [4] International Expansion - Partnering with French company Laboratoire Bailly-Creat for African and Southeast Asian markets [4] - Targeting Africa's pharmaceutical market with a population of 1.4 billion and annual drug consumption of over 10 billion USD [5] - Expanding to "Belt and Road" countries, with China having signed over 200 cooperation documents with 152 countries [5] R&D and Innovation - Obtained four new consistency evaluation approvals in 2024 [6] - Currently has 27 approved or deemed approved specifications and 8 R&D projects [6] - Transitioning from generic drugs to innovative drugs, with two new 2.2 class solid preparations initiated in 2024 [6] - R&D investment consistently exceeds 10% of revenue [7] Future Plans - Considering equity incentives and employee stock ownership plans [7] - Focusing on mergers and acquisitions to enhance product portfolio and scale [8] - Targeting innovative drugs, biological drugs, and companies with technical or policy barriers [8]

Financial Performance - The company's operating revenue for Q3 2024 reached ¥89,552,626.84, representing a year-on-year increase of 137.26%[2] - The net profit attributable to shareholders for Q3 2024 was -¥6,489,699.32, with a year-to-date net profit of -¥46,889,888.23[2] - The basic earnings per share for Q3 2024 was -¥0.01, and the diluted earnings per share was also -¥0.01[3] - The company achieved a year-to-date operating revenue increase of 53.34%, driven by enhanced product promotion and channel utilization[6] - Total operating revenue for the first three quarters of 2024 reached ¥231,030,545.43, a significant increase of 53.3% compared to ¥150,665,541.41 in the same period of 2023[19] - The company reported a net loss of ¥46,889,888.23 for the first three quarters of 2024, an improvement from a net loss of ¥96,582,500.85 in the same period of 2023[21] - Operating profit (loss) improved to -¥52,997,337.55 from -¥93,993,126.65 year-over-year[21] - Basic and diluted earnings per share improved to -¥0.07 from -¥0.13 year-over-year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,205,651,919.73, a decrease of 25.79% compared to the end of the previous year[3] - The total assets decreased to ¥1,205,651,919.73 from ¥1,624,560,125.88, a decline of 25.7%[18] - The company’s equity attributable to shareholders decreased by 8.09% year-on-year, totaling ¥855,722,332.04[3] - The total liabilities decreased to ¥349,929,587.69 from ¥693,517,978.39, a reduction of 49.6%[18] - Current assets totaled RMB 495,170,740.50, down from RMB 881,533,254.03 in the previous period, indicating a significant reduction[16] - Non-current assets totaled RMB 710,481,179.23, down from RMB 743,026,871.85, indicating a decrease of about 4%[17] Cash Flow - The company reported a net cash flow from operating activities of -¥64,056,674.63 for the year-to-date period[3] - The net cash flow from operating activities for the first three quarters of 2024 was -64,056,674.63 RMB, compared to -21,150,724.69 RMB in the same period of 2023, indicating a decline in operational cash flow[25] - Total cash inflow from operating activities decreased to 211,980,745.20 RMB in 2024 from 260,896,973.39 RMB in 2023, reflecting a year-over-year decline of approximately 18.7%[25] - Cash outflow from operating activities was 276,037,419.83 RMB in 2024, slightly down from 282,047,698.08 RMB in 2023, showing a decrease of about 2.5%[25] - The company reported a significant reduction in cash flow from operations, impacting liquidity and operational flexibility[16] Investments and Financing - The company received government subsidies amounting to ¥14,483,829.44 year-to-date, which positively impacted its financial performance[4] - Cash inflow from investment activities was 196,544,899.48 RMB in 2024, significantly lower than 599,270,726.35 RMB in 2023, representing a decline of approximately 67.2%[25] - The net cash flow from investment activities improved to 185,104,669.99 RMB in 2024, compared to -89,657,920.92 RMB in 2023, indicating a positive turnaround[25] - Cash inflow from financing activities was 222,004,918.60 RMB in 2024, up from 118,646,944.44 RMB in 2023, marking an increase of approximately 87.2%[25] - The net cash flow from financing activities was -314,288,040.40 RMB in 2024, worsening from -4,127,640.96 RMB in 2023, indicating increased financial strain[25] Operational Changes - The company is actively seeking CMO orders to maximize production capacity and reduce costs[7] - There were no new product launches or major strategic initiatives mentioned during the earnings call, indicating a focus on financial restructuring and cost management[16] - Research and development expenses decreased to ¥14,987,666.90, down 29.5% from ¥21,226,696.58 in the previous year[19] - The company reported a significant increase in cash paid for purchasing goods and services, rising to 145,189,289.44 RMB in 2024 from 107,302,510.84 RMB in 2023, an increase of approximately 35.3%[25] - Cash paid for employee compensation decreased to 36,462,803.02 RMB in 2024 from 41,659,416.41 RMB in 2023, reflecting a decrease of about 12.0%[25]

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2024-071 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （三）根据《上海证券交易所股票上市规则》等相关规定以及《灵康药业集 团股份有限公司公开发行可转换公司债券募集说明书》（以下简称"募集说明书"） 的有关约定，公司该次发行的"灵康转债"自 2021 年 6 月 7 日起可转换为本公 司 A 股普通股股票，目前转股价格为 8.00 元/股。 1 （四）因"灵康转债"触发《灵康药业集团股份有限公司公开发行可转换公 司债券募集说明书》中约定的回售条款，公司于 2024 年 6 月 24 日至 2024 年 6 月 28 日进行了回售，回售数量为 2,048,260 张，回售资金已于 2024 年 7 月 3 日 发放。 二、可转债本次转股情况 "灵康转债"自 2024 年 7 ...